ABSTRACT
BACKGROUND

Clostridium difficile, recently reclassified as Clostridioides difficile
1 is capable of inducing diarrheal disease (C. difficile infection, CDI) due to the production of secreted toxins. 2 After CDI treatment, the risk of a recurrence within eight weeks is 15-25%%, which rises to 40-65% in patients with multiple recurrences. 2, 3 Recurrences are associated with clinically severe diarrhea and persistent disturbance of the colonic microbiota. 4 Fecal Microbiota Transplantation (FMT) is therefore a very effective treatment for recurrent CDI, with cure rates close to around 85%. 5, 6 Large scale implementation of FMT in daily clinical practice is hampered by lack of easily available donor feces and safety concerns. A centralized stool bank can overcome these hurdles.
AIM AND STRUCTURE OF A NON-PROFIT STOOL BANK
The overall and primary aim of a stool bank is to provide on a (inter) national or regional level, ready to use, high-quality donor feces solutions to treat patients with recurrent or refractory CDI. Secondly, a central stool bank should enable careful monitoring of treatment outcome, side effects and long term effects of FMT.
Therefore, the stool bank should preferably be facilitated by a well-equipped biobank to store an aliquot of the donor feces, and samples of all delivered fecal suspensions, to guarantee traceability in case of adverse events. A stool bank is ideally entwined with a clinical microbiological department as the expertise and equipment to perform both various screening tests, and to process fecal suspensions is already present.
Since FMT is not yet an approved, treatment modality by the European Medicines Agency (EMA) or US Food and Drug Administration (FDA), commercial stool banks are not the preferred suppliers. A stool bank working group should consist of experts in the fields of Microbiology, Infectious Diseases, Gastroenterology, Biobanking, Methodology, and if donor feces is considered as a drug; Pharmacology. An overview of the currently existing donor feces banks is depicted in Table 1 . Similar as to the NDFB, most of the donor banks are non-profit and primarily use FMT for treatment of patients with recurrent CDI.
LEGISLATION OF A DONOR FECES BANK
There is still considerable confusion about the regulatory aspects of FMT. [7] [8] [9] [10] The FDA dictates that adequate informed consent must be obtained before use of FMT products. 11 In the European Union (EU), a standardized policy is lacking and each member state is allowed to have its own policy. In The Netherlands, FMT is currently regarded as an unclassified treatment approach, which is allowed (if applied safely), for patients with recurrent CDI, or in the context of an approved investigational study protocol.
Although FMT appears a typical transplantation product to most experts in the field 12 , it does not fulfil the criteria for guidance by the EU tissue and cell transplantation act, because the cellular component of FMT appears not to be the active substance.
Furthermore, human excretions are excluded by the US act for tissue and cell transplantations. As a consequence, several European countries are considering donor feces as a drug (Table 1) , which has major regulatory implications negatively influencing future availability and pricing of donor stool solutions for FMT. Application as a drug has the consequence that the proposed drug would have to be identical in active ingredient, dosage form, route of administration, quality, and performance characteristics. However, the complexity of the microbial community in stool and the variability across stool samples makes it impossible to guarantee the contents from batch to batch. Furthermore, it would have the consequence of putting fecal material for use in FMT under the jurisdiction of hospital pharmacies, requiring storage of the fecal product in the pharmacy itself. In this regard, common sense and consultation of the experts in the field may hopefully result in adjustment of the EU law in concordance with the rapid scientific developments, enabling a future status of donor feces as transplantation product.
HOW TO RECRUIT DONORS
Historically, FMT donors were conveniently selected among close relatives and friends of patients with the underlying idea that they would have at least a partially shared microbiome, increasing the chances of success 13 , and limiting the risk of pathogen transmission. 13, 14 However, later evidence showed that FMT with donor feces from unrelated donors was as effective. 5, 15 This finding provided an opportunity for a better standardized, safer, faster and cheaper method of donor selection, screening and fecal suspension preparation.
The NDFB acquired many potentially interested donors after announcing the opening of the first Dutch stool bank via local and national media (e.g. paper, national news).
One of several options for recruitment of feces donors are amongst established blood donors, as this has the advantage of previously screened, healthy and motivated
volunteers. An important difference in the donor recruitment in The Netherlands and most other European countries (except Germany) compared to the USA is that it is prohibited to offer a paid reimbursement for blood (or stool) donations. This prohibition, is in line with the blood donating advice of the World Health Organization which states that the safest blood donors are voluntary, non-remunerated donors. 16 As it is important to limit the time between defecation and delivery of the feces, to preserve as much anaerobes, donors should be recruited in the near proximity of stool banks, such as non-health care workers of the hospital and personnel of companies in the neighborhood.
DONOR SCREENING BY QUESTIONNAIRE AND INTERVIEW
All potential donors are extensively screened by a questionnaire and a personal interview concerning risk factors for transmissible diseases and factors influencing the intestinal microbiota ( Table 2 ). The NDFB has applied an arbitrary age limit of 18 to 50 years, assuming that above the age of 50 years a significant increase of comorbidities with a less stable microbiota can be present. 17 A body mass index (BMI) > 25 kg/m2 is also an exclusion criterion, since obesity may also be associated with a specific microbiota composition. 18 Moreover, one case-report, and an experimental animal study suggesting new-onset obesity after infusion of donor feces of an overweight donor has been reported. 19, 20 Any other gastrointestinal disorder (e.g. irritable bowel syndrome (IBS), Crohn's disease and ulcerative colitis) also qualifies as an exclusion criterion of donation. 21 Other exclusion criteria that have been shown to be related to aberrant microbiota composition are depicted in box 1. 22 The list of exclusion criteria will probably expand in the future when other conditions are found to be associated with an altered microbiota composition. Enterovirus and Parechovirus are usually asymptomatic but can cause skin disease (and-foot-and-mouth disease), pleurodynia, myocarditis and meningitis. 42, 43 Adenovirus non-40/41 can cause myocarditis. 44 In addition, feces is screened for Hepatitis E, which is frequently found in asymptomatic (blood) donors. 45 To prevent transmission and development of systemic infections, potential donors are screened with PCRs for all the above mentioned viruses (see also The serostatus of the donor is determined for Epstein-Barr virus (EBV) and Cytomegalovirus (CMV). Immunocompromised patients will be matched accordingly for safety reasons. However, the risk of transmission is not established and we await the results of ongoing study regarding the risk of CMV transmission due to FMT (TRANSDECMV Clin Trial Gov: NCT02694484).
Approximately two months after the initial screening, a new donor sample of feces and blood are screened again, using similar tests as applied at entry of the program (see Table2) , except for CMV and EBV which are repeated once a year (in case of a negative serostatus. After a successful second screening, the donor fecal suspensions collected until two weeks prior to the second screening are released for patient treatment. This quarantine period minimizes the risk for transmissible diseases.
COLLECTION, PREPARATION, AND STORAGE OF DONOR FECES SUSPENSIONS
It is generally believed that a high viability of bacteria in stools increases the chance of successful FMT. Since the majority of fecal bacteria are anaerobic, feces needs to be processed within six hours after defecation. 5, 6 To prevent environmental contamination, feces is collected by the donor in a fecal container (for instance Fecotainer™). For suspension, approximately 60 gram of donor feces is used based on the data of a systematic review suggesting a decreased cure rate with < 50 gram. 53 The feces is homogenized with saline using a mortar and pestle, whereas some laboratories use a commercial blender. 15, 37 Disadvantages of blenders are difficulties with appropriate sterilization and aerosolization of the feces. A metal sieve (mesh 300µm) is used to remove undigested food fragments. The fecal suspension is then concentrated by centrifugation (15 minutes, 6000g) 37 and glycerol is added as cryoprotectant to a final concentration of 10% in a total end volume of 200 ml. A recent study showed that frozen fecal suspension is equally effective as a fresh fecal suspension for the treatment of CDI. 54 This allows stool samples to be stored at -80°C for a longer period of time until the donor has been retested prior to actual use of the donor feces. Clinical success of frozen suspensions is reported until five to six months of storage at -80°C, but could be much longer, in theory. Like OpenBiome, the NDFB uses a storing period of two years. 
HOW TO APPLY SAFETY MEASURES AND INCLUDE QUALITY CONTROLS
HOW TO DETERMINE ELIGIBILITY OF PATIENTS WITH RECURRENT CDI FOR FMT
Since the effectiveness of FMT has only been recognized by the authorities for recurrent CDI, it is extremely important to diagnose recurrent CDI both with the For a first recurrence of CDI, it is advised to first treat the patient with another course of antibiotics. Fidaxomicin could be considered because of potentially relapse reducing effect due to its narrow antibiotic spectrum. 56 In general, FMT is advised in patients with multiple recurrences. However, in some cases of severe, therapy refractory CDI, FMT could be considered for a first recurrence. 39, 57 A recently completed study suggests that intravenously administered humanized monoclonal antibodies against C. difficile toxin B (bezlotoxumab) protects against (multiple) recurrent CDI. However, it is yet unclear which patients really benefit from this very expensive treatment strategy. 58 Pregnancy, severe food allergy, and antibiotic usage other than for C. difficile at the day of expected infusion are exclusion criteria for FMT treatment. Although, recently, the first case report of successful and safe FMT in a pregnant patient has been published. 59 All potential risks, benefits, logistics, and procedural details are discussed with the patient by the treating physician.
WHAT IS THE PROCEDURE OF FMT
If the patient is eligible for treatment with FMT, donor feces suspension is transported to the referring hospital on dry ice. Prior to transplantation, the feces suspension is thawed (overnight in a 4°C refrigerator or during five hours at room temperature), based on literature and our expert opinion. 15, 54, 60 The donor feces suspension may be kept at room temperature for up to three hours or refrigerated at 4°C for up to six hours. Samples should never to be re-frozen, because freeze-thaw cycles may compromise stability and efficacy of the sample, possibly due to loss of viability. To eradicate vegetative cells of C. difficile, prior to FMT (until one day before the procedure), patients receive vancomycin (125-250 mg QID) for a minimum of four days, followed by two liters of bowel lavage one day prior to FMT. 5 Whether bowel lavage can be excluded from the protocol is currently a matter of discussion, since recent reports have shown similar efficacy for FMT without bowel lavage. [61] [62] [63] The treating physician is advised to avoid antibiotics in FMT patients during the first month after FMT unless strictly necessary, and preferably as small as possible. and patients are monitored for two hours. If FMT through a duodenal tube is contraindicated (i.e. due to a hampered bowel passage or higher risk of aspiration), FMT is performed via colonoscopy. We generally do not advice enemas, because of the need of repeated FMT's to achieve a high cure rate with enemas.
NDFB EXPERIENCE DURING MAY -JANUARY 2017
In March 2016, the opening of NDFB was reported in various local and national newspapers and broadcasted in radio and television programs, accompanied by an invitation for volunteers to register as donor. Subsequently, 165 volunteers registered and informed by email about the procedure and were requested to complete an online questionnaire. After this evaluation only 21 potential donors (12.7%) were screened for the presence of transmissible diseases (Table 3) . Nine (5.5% of initial responders) volunteers passed the screening and were invited to donate. This percentage is low, though in line with earlier reports on donor screening. 40, [67] [68] [69] The fecal suspensions were quarantined for two months after which the donors were rescreened. Two volunteers had to temporarily stop donating for three months because of an episode of acute diarrhea. Four donors did not pass a re-screening: two carried B. hominis, one an ESBL positive E.coli (exclusion for at least 6 months) and one donor a rotavirus (indication for re-screening of the previous donated samples and exclusion for 2 weeks); this underlines the importance of a quarantine period.
As a substantial portion of donors only donates temporarily, donor recruitment is a continuous process. In May 2016, the first FMT with a donor feces suspension of the NDFB was performed. In the first nine months after its opening, 31 feces suspensions to 18 different hospitals throughout The Netherlands have been distributed for treatment with FMT. We noticed a cure rate of 84%, which is in line with the earlier reported randomized controlled trails. 
